Clinical Trial Search

Primary: Percentage of Participants Experiencing at Least One Adverse Event (AEs) in the Core Period — 96.3; 100.0 percentage of participants

Primary: International Index of Erectile Function (IIEF-EF) Questionnaire — 18; 17.9; 20.5; 19.7 score on a scale — p=<0.007

Primary: Sniffin' Sticks Test Score — 25.96; 36.40 score on a scale

Primary: Overall Response Rate — 3 Participants

Primary: Plasma Amine Oxidase Copper-containing 3 (AOC3) Activity After 12 Weeks of Treatment, Relative to Baseline in Percent — 102; 24.0; 13.1; 8.27 Percentage relative to…

Primary: Percentage of Participants With Lens Centration Assessment by the Investigator - Methafilcon A Contact Lenses — 100; 0; 0 percentage of participants

Primary: Maximum Satiation — 892.5; 951.75; 655.5; 892.5 mL — p=0.12

Primary: Number of Treatment Emergent Adverse Events (TEAEs). — 27; 9 events

Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants

Primary: Maximum Plasma Concentration (Cmax)-Budesonide — 702.3; 452.6; 340.0; 612.0 pg/mL

Primary: Successful Removal of the Uterus Without Conversion to Another Technique — 35; 35 Participants — p=0.0221

Primary: Co-Primary Outcome: Body Mass Index (BMI) — 35.9; 36.6 kg/m^2

Primary: Pain (Brief Pain Inventory - Short Form) - Pain Severity — -.87; -.24 units on a scale — p=.25

Primary: Change From Baseline in the CGI-21 Anxiety — 4.9; 2.9; 3.4 score on a scale — p=<.05

Primary: Number of Participants With Attacks — 0 Participants